Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration‐resistant prostate cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0045|73|12|1291-1305

ISSN： 0270-4137

Source： THE PROSTATE, Vol.73, Iss.12, 2013-09, pp. : 1291-1305

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

By  

THE PROSTATE, Vol. 75, Iss. 8, 2015-06 ,pp. : 836-844

John Wiley & Sons Inc

Access to resources Recommend Favorite

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

By  

Oncology, Vol. 91, Iss. 5, 2016-08 ,pp. : 267-273

Karger

Access to resources Recommend Favorite

Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration‐resistant prostate cancer: A retrospective study

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 278-278

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

John Wiley & Sons Inc

Access to resources Recommend Favorite

Methylselenocysteine preventing castration‐resistant progression of prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 9, 2015-06 ,pp. : 1001-1008

John Wiley & Sons Inc

Access to resources Recommend Favorite